This protocol addresses fibrocystic breast changes (ICD-11 GB20.0) in the specific situation where prior medical therapy targeting breast pain has not achieved its clinical goal after reassessment at 2 months, and a further step is required.
The preceding management included tamoxifen or danazol, with the clinical target of alleviating fibrocystic breast disease symptoms — specifically breast pain — reassessed at 2 months. When that target is not met, this protocol defines the structured next step.
At this stage, a surgical option enters consideration. It is approached only after thorough patient counseling and represents the last resort in the management pathway. The complete protocol specifies the precise indications and the structured decision sequence that guides this step.